31 completed, 10 terminated, 7 withdrawn, 4 recruiting. 36 Phase 2, 27 Phase 1, 8 Phase 3, 3 Early Phase 1, 1 Not applicable.
Follow Fibroblast Growth Factor 7: new trials by email Literature Review of Fibroblast Growth Factor 7 trials Research Report on Fibroblast Growth Factor 7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-27 | 2026-10-22 |
| Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study Base-edited hematopoietic stem and progenitor cells, Alemtuzumab, Sirolimus - CD40L-HyperIgM Syndrome | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 1 | 2025-07-16 | 2026-07-31 |
| Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin - Crohn Disease | Phase 1 / Phase 2 | Not yet recruiting | Stanford University | 14 | 2025-07-01 | 2025-05-23 |
| Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy Plerixafor, Filgrastim, Palifermin - X-linked Severe Combined Immunodeficiency, X-SCID | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2025-05-09 | 2026-10-13 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 7 | 2022-07-19 | 2026-07-06 |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2021-04-30 | 2026-07-13 |
| Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia Keratinocyte growth factor - Alopecia, Chemotherapy-Induced Change | Early Phase 1 | Completed | University of Arizona | 28 | 2020-04-27 | 2022-12-16 |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide - Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient | Phase 1 | Withdrawn | City of Hope Medical Center | 2018-12-30 | 2018-12-07 | |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2018-01-01 | 2017-12-13 | |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Palifermin, Panobinostat, Gemcitabine - Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2017-06-01 | 2017-04-21 | |
| Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Lenalidomide, Vorinostat, Gemcitabine - Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2016-06-22 | 2019-12-13 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Rituximab, Conditioning chemotherapy, TMS - Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2015-09-24 | 2025-09-30 |
| A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab - Neuroepithelial Tumor, Solid Tumor | Early Phase 1 | Terminated | Montefiore Medical Center | 1 | 2015-09-01 | 2017-08-17 |
| Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation Palifermin - Mucositis | Phase 3 | Unknown | The Catholic University of Korea | 88 | 2015-01-01 | 2014-12-10 |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma Carfilzomib, SAHA, Gemcitabine - Myeloma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2014-09-01 | 2014-07-11 | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - T-cell Non-Hodgkin Lymphoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2013-07-01 | 2023-01-30 |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Palifermin, Lupron, peripheral blood stem cell transplantation - Leukemia, Multiple Myeloma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 82 | 2012-12-01 | 2026-01-07 |
| Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector, Busulfan, Palifermin - X-linked Severe Combined Immunodeficiency (XSCID) | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2012-09-25 | 2026-10-22 |
Showing 20 of 60. Sign in to see all of them.
Stomatitis (12) · Hodgkin Disease (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Multiple Myeloma (9) · Leukemia (8) · Leukemia, Myeloid, Acute (8) · Mucositis (7) · Neoplasms (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Head and Neck Neoplasms (5) · Lymphoma, Large B-Cell, Diffuse (5) · Myelodysplastic Syndromes (5) · Graft vs Host Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4)
Swedish Orphan Biovitrum (11) · M.D. Anderson Cancer Center (9) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · City of Hope Medical Center (5) · Amgen (3) · Memorial Sloan Kettering Cancer Center (3) · Barbara Ann Karmanos Cancer Institute (1) · Brett King (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Children's Oncology Group (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · European Society for Blood and Marrow Transplantation (1) · FDA Office of Orphan Products Development (1) · Jonsson Comprehensive Cancer Center (1)
United States (39) · Canada (2) · Germany (2) · United Kingdom (2)
Suk S De Ravin, M.D. (5) · Yago Nieto, MD, PHD (3) · Yago Nieto, MD, PhD (2) · Yago Nieto, MD,PHD (2) · Adele K. Fielding (1) · Alain Mina, M.D. (1) · Alasdair Coles, Phd FRCP (1) · Angela Christiano, PhD (1) · Ashok Srinivasan, MD (1) · Christos E. Emmanouilides, MD (1) · David I. Rosenthal, MD (1) · Dietger Niederwieser, Professor (1) · Eric W. Hedrick, MD (1) · George Somlo, MD (1)
PMID 25880826, PMID 33951890, PMID 15602019, PMID 16391299, PMID 16415901, PMID 17580258, PMID 20855800, PMID 26071868, PMID 27480385, PMID 28522110, PMID 31063156, PMID 34477813, PMID 35358441, PMID 35358442, PMID 35764638, PMID 39413163, PMID 40331908, PMID 41834767
P30CA033572 (2), 2009 (1), P30CA022453 (1), U10CA095861 (1)